(E)-α-[(TriphenylMethoxy)iMino]-2-[(triphenylMethyl)aMino]-4-thiazoleacetic Acid
![(E)-α-[(TriphenylMethoxy)iMino]-2-[(triphenylMethyl)aMino]-4-thiazoleacetic Acid price.](/CAS/GIF/69689-81-2.gif)
|
- $650 - $1320
- Product name: (E)-α-[(TriphenylMethoxy)iMino]-2-[(triphenylMethyl)aMino]-4-thiazoleacetic Acid
- CAS: 69689-81-2
- MF: C43H33N3O3S
- MW: 671.82
- EINECS:
- MDL Number:MFCD09031337
- Synonyms:(E)-2-(TrityloxyiMino)-2-[2-(tritylaMino)thiazol-4-yl]acetic Acid;(E)-α-[(TriphenylMethoxy)iMino]-2-[(triphenylMethyl)aMino]-4-thiazoleacetic Acid;4-Thiazoleacetic acid, α-[(triphenylmethoxy)imino]-2-[(triphenylmethyl)amino]-, (E)- (9CI);(E)-α-[(TriphenylMethoxy)iMino]-2-[(triphenylMethyl)aMino]-4-thiazoleacetic Acid
2 prices
Selected condition：
Brand
- Medical Isotopes, Inc.
- TRC
Package
- 25mg
- 250mg
- ManufacturerMedical Isotopes, Inc.
- Product number72945
- Product description(E)-2-(Trityloxyimino)-2-[2-(tritylamino)thiazol-4-yl]aceticAcid
- Packaging25mg
- Price$650
- Updated2021-12-16
- Buy
- ManufacturerTRC
- Product numberT889440
- Product description(E)-2-(Trityloxyimino)-2-[2-(tritylamino)thiazol-4-yl]aceticAcid
- Packaging250mg
- Price$1320
- Updated2021-12-16
- Buy
| Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|
| Medical Isotopes, Inc. | 72945 | (E)-2-(Trityloxyimino)-2-[2-(tritylamino)thiazol-4-yl]aceticAcid | 25mg | $650 | 2021-12-16 | Buy |
| TRC | T889440 | (E)-2-(Trityloxyimino)-2-[2-(tritylamino)thiazol-4-yl]aceticAcid | 250mg | $1320 | 2021-12-16 | Buy |
Properties
Boiling point :832.8±75.0 °C(Predicted)
Density :1.19±0.1 g/cm3(Predicted)
solubility :Dimethyl Formamide, Dimethyl Sulfoxide
form :Solid
pka :2.38±0.41(Predicted)
color :Off-white
Density :1.19±0.1 g/cm3(Predicted)
solubility :Dimethyl Formamide, Dimethyl Sulfoxide
form :Solid
pka :2.38±0.41(Predicted)
color :Off-white
Safety Information
| Symbol(GHS): | ||||||||
|---|---|---|---|---|---|---|---|---|
| Signal word: | ||||||||
| Hazard statements: |
|
|||||||
| Precautionary statements: |
|